Company ProfilePremium

Medicskin Holdings Limited

Company Profile Analysis

Ticker: 8307.HK密迪斯肌控股有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Medicskin Holdings Limited - Company showcase

Year Founded & Workforce

2000

42 Employees

Medicskin Holdings Limited logo

Medicskin Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Medicskin Holdings Limited Overview

Medicskin Holdings is a micro-cap, founder-controlled medical aesthetics and dermatology clinic operator. All of its revenue comes from Hong Kong. It runs two doctor-led "Medicskin" medical skincare centres in prime locations: a full floor at New World Tower in Central and a centre at Ocean Centre in Tsim Sha Tsui. These are supported by the complementary "facematter" treatment and skincare brand and a small anti-ageing and preventive-medicine offering.

FY2026 revenue was HK$47.9 million. Of this, 81.8% came from prepaid courses of non-invasive and minimally invasive treatments: injectables, energy-based devices, HIFU and thread lifts. The group's main differentiators are its physician-performed model, anchored by a founder-dermatologist with more than 30 years in medical aesthetics, and a loyal client base (most clients have used its services for over five years).

Its main constraints are scale and structure. It is about 1/20th the size of Perfect Medical and about 1/80th the size of EC Healthcare. It has a heavy fixed-cost base, thin equity of HK$5.2 million, and a persistent net current liability position caused by HK$23.2 million of customer prepayments. FY2026 marked a return to a small profit after three loss-making years.


Company's own description (latest annual report)

In AR26 the company describes itself as a medical skincare service provider in Hong Kong. Its "Medicskin"-branded centres are strategically located in New World Tower, Central (a core business hub) and Ocean Centre, Tsim Sha Tsui (a prime shopping district with harbour views). Medicskin specialises in medical skincare services provided by registered medical practitioners. The "facematter" brand offers medical aesthetic and lifestyle beauty treatments that complement Medicskin. Facematter skincare products are sold through the group's own online shop and a third-party shopping platform [AR26].

Clinical focus covers two areas [AR26]:

Medical dermatology: acne, pigmentation, rosacea, dermatitis, eczema and warts.

Aesthetic improvement: skin rejuvenation, facial sculpting, body contouring, acne scars and enlarged pores, removal of undesirable naevi (moles), and hair removal.

The company states that most clients are long-term clients who have patronised the group for more than five years [AR26].

Revenue model

Revenue is generated through three disclosed service lines, all within a single reportable operating segment [AR26]:

  1. Medical consultation services: private consultations for examination and diagnosis of skin conditions, with recommendations of skincare products or treatments. Recognised over time as the service is provided. FY2026: HK$954k (2.0% of revenue).

  2. Prescription and dispensing services: prescription and dispensing of pharmaceutical products, medication and skincare products, including retail skincare sales. Recognised at a point in time when goods are collected or delivered. FY2026: HK$7,778k (16.2%).

  3. Treatment services: non-invasive and minimally invasive procedures. These typically involve injection of botulinum toxin type A and hyaluronic acid, cauterisation, thread lifting, and device-based treatments using laser, radio-frequency (RF), high-intensity focused ultrasound (HIFU) and high-intensity facial electrical stimulation (HIFES). FY2026: HK$39,139k (81.8%).

Prepaid package mechanics. Treatment services are mostly sold as prepaid treatment packages. Cash received is deferred as a contract liability and recognised as revenue when treatments are delivered (an output method). Unused portions ("breakage") are recognised when the likelihood of redemption becomes remote, or in full when the package's service period expires [AR26]. At 31 March 2026, contract liabilities were HK$23.2 million. That is about 48% of annual revenue, and management expects it to be recognised over 12–36 months [AR26].

Value chain position

Medicskin is a downstream, consumer-facing clinical service provider. It buys pharmaceuticals, injectables, skincare products, treatment consumables and capital equipment from suppliers. In FY2026 it bought from 76 Hong Kong suppliers, 3 US suppliers and 1 Korean supplier [AR26]. Pharmaceuticals come only from licensed Hong Kong drug distributors.

Supplier concentration is meaningful. The largest supplier accounted for 18.5% of purchases and the top five for 56.3% (FY2025: 18.2% and 61.0%) [AR26]. Treatment devices are selected by the group's doctors and must be approved by the US FDA or Korea's MFDS, be CE-marked, or be supported by independent medical journals and clinical data [AR26].

The group does not manufacture. Facematter products are described as developed by a team with more than 20 years in cosmeceuticals [WEB]. Whether manufacturing is outsourced, and to whom, is not publicly disclosed.

Customer types and end-markets

Customers: individual retail consumers, overwhelmingly in Hong Kong. Customer concentration is negligible: the top five customers were under 4.4% of revenue (FY2025: 3.4%), and no customer exceeded 10% [AR26].

End-markets: - Hong Kong medical aesthetics, the core market.

  • Medical dermatology, the clinical niche.

  • Professional skincare retail, through the facematter e-shop.

  • Anti-ageing and preventive medicine: personalised wellness plans, genetic testing, and anti-ageing medicine and supplements [WEB].

Geography: 100% of external revenue comes from Hong Kong [AR26].

Independent characterisation

Medicskin is effectively a two-clinic, owner-physician practice wrapped in a listed holding structure. The economic engine is three things working together:

  • the founder's clinical reputation;

  • a loyal, mature client base that buys prepaid treatment courses;

  • periodic refresh of the device and injectable menu (FY2026: Ultherapy PRIME®) to keep existing clients spending.

The model has attractive unit-level features:

  • about 81% gross margin after consumables and products;

  • customer prepayments that fund working capital;

  • negligible receivables.

It is, however, burdened by structurally high fixed costs:

  • staff costs were 47.6% of revenue in FY2026;

  • prime-location rent (right-of-use depreciation plus lease interest) was about 12.4% of revenue;

  • directors' emoluments alone were 18.2% of revenue.

The result is extreme operating leverage. A swing of roughly ±5% in revenue moves the group between profit and loss. The company has a stated ambition to expand in Hong Kong and Mainland China [AR26][WEB]. In practice it has done the opposite: it disposed of a dormant Guangzhou subsidiary in FY2026 and has kept the same two-centre footprint. Its listed status adds compliance costs (audit fee HK$420k, plus GEM governance overhead) that are large relative to its earnings.

Strategy

Stated corporate strategy (AR26 MD&A and website, paraphrased)

The group's stated business strategy has three pillars [AR26][WEB]:

  1. Expand presence: strategically expand and strengthen its presence in Hong Kong and Mainland China.

  2. Enhance offerings: continuously improve the quality and variety of services and products.

  3. Maintain expertise: maintain and enhance professional expertise.

The overarching aim is to create value and maximise returns for shareholders while providing reliable, high-quality professional services. Recurring themes in the FY2026 Chairman's Statement and Outlook [AR26]:

Cost discipline and operational optimisation: to counter intense competition and high operating costs.

Technology leadership: adopting cutting-edge treatment technologies (example: Ultherapy PRIME®).

Marketing: investment in online and social-media marketing, supplemented by targeted promotions such as new-treatment launch campaigns.

Centre renovation: planned renovation of the medical skincare centre(s) to raise service quality.

Cautious optimism: expects global uncertainty and intense competition in medical aesthetics in 2026, but sees steady medium- to long-term demand growth as medical aesthetics becomes a mainstream health and beauty solution, with growing acceptance of non-surgical and minimally invasive treatments.

There has been no investor day; the company does not hold earnings calls or publish investor presentations.

Strategic initiatives (last 24 months)

InitiativeTimingDetailTarget / metricSource
Lease renewals at lower rentFeb 2025 (benefit realised FY2026)Centres and office leases renewed; RoU depreciation down 26%HK$1.9m annual saving in FY2026[AR26]
Cost-saving programmeFY2026Lower directors' emoluments and staff salariesStaff costs down HK$1.1m (-4.6%)[AR26]
Ultherapy PRIME® launchFY2026Upgraded micro-focused ultrasound lifting with DeepSEE® imagingNot quantified[AR26]
Digital and social-media marketing pushFY2026Online and social-media promotion; new-treatment launch campaignsNot quantified[AR26]
Consolidation of preventive-medicine unit1 Oct 2024Buy-out of 49% minority in Rightway Honour for US$2Simplified ownership[AR26]
Back-office relocationLate 2024Move to Sheung Wan office with central air-conditioningElectricity use down 14.1% in FY2026[AR26]
PRC rationalisationFY2026Disposal of dormant Guangzhou subsidiaryImmaterial[AR26]
Centre renovationPlanned (timing not disclosed); Central lease extended to 2030 to cover itUpgrade of Central centreCapex amount not disclosed; capital commitments HK$0.5m for PP&E at 31 Mar 2026[AR26][DT1006]
New share option schemeAdopted 27 Sep 2024Up to 39,673,600 shares (10%); service-provider sublimit 7,934,720 (2%); about 8 years remainingNo grants yet[AR26]
ESG targets (2026–2028)Set against 2023 baselineGHG intensity -1%, energy intensity -1%, non-hazardous waste intensity -3% (cumulative)All already exceeded in FY2026[AR26]

Medium-term financial targets and guidance

No quantitative medium-term financial targets, revenue guidance or margin targets are publicly disclosed. The only forward-looking financial signal is the qualitative "cautiously optimistic" outlook [AR26].

Products & Services

The group discloses its portfolio at the level of treatment modality and brand, not SKU. Pricing for treatments and packages is not publicly disclosed in filings. The table goes item by item at the most granular level disclosed.

Medicskin Medical Skincare Centres (core brand)

OfferingDescription / capabilitiesTarget customerLaunch / latest versionPricing modelSource
Medical consultationPrivate doctor consultation; examination and diagnosis of skin conditions; tailored product and treatment recommendationsPatients with skin disease; aesthetic clients at intakeSince 2000Per-visit fee (amount not disclosed)[AR26]
Prescription & dispensingPrescription and dispensing of medicines, pharmaceutical products and skincare products; labelling to statutory standardsExisting patientsSince 2000Per item (not disclosed)[AR26]
Acne treatmentMedical and procedural management of acneTeens and adults with acneOngoingCourse/package (not disclosed)[AR26][WEB]
Pigmentation treatmentLaser/light-based and medical management of pigmentationAdults with melasma, spots and similarOngoingCourse/package[AR26]
Rosacea, dermatitis, eczema, wartsMedical dermatology treatments (including cauterisation for warts)Patients with inflammatory or infective skin diseaseOngoingConsultation plus prescription[AR26]
Skin rejuvenationEnergy-based devices (laser, RF), injectablesAgeing-skin clientsOngoingPrepaid course[AR26]
Facial sculpting / contouringBotulinum toxin type A, hyaluronic acid dermal fillers, thread lifting, HIFUAesthetic clientsOngoingPrepaid course[AR26][dividend.watch profile]
Body contouringDevice-based body contouring (specific devices not named in AR26)Aesthetic clientsOngoingPrepaid course[AR26]
Acne scars & enlarged poresLaser and RF resurfacingPost-acne clientsOngoingPrepaid course[AR26]
Naevi (mole) removalRemoval of undesirable naevi (cauterisation/laser)GeneralOngoingPer procedure[AR26]
Hair removalLaser/light-based hair removalGeneralOngoingPrepaid course[AR26]
Ultherapy PRIME® (flagship launch FY2026)Upgraded Ultherapy®. Micro-focused ultrasound delivers energy to deep skin layers; enhanced DeepSEE® real-time imaging visualises skin layers so energy reaches the SMAS fascia; stimulates collagen and elastin for lifting and tightening.Clients seeking non-surgical liftingIntroduced during FY2026Per session/package (not disclosed)[AR26]
HIFES treatmentsHigh-intensity facial electrical stimulation (muscle-toning facial treatments)Aesthetic clientsDisclosed in AR26Prepaid course[AR26]
RF and laser platformsRadio-frequency and laser devices (brand names not disclosed); devices must be FDA/MFDS/CE-approved or clinically supportedAesthetic and dermatology clientsOngoing; equipment refreshed (FY2026 additions HK$1.69m medical equipment)Prepaid course[AR26]

facematter (brand)

OfferingDescriptionTarget customerChannelSource
facematter medical-aesthetic and lifestyle beauty treatmentsComplements Medicskin with medical-aesthetic and lifestyle beauty servicesAesthetic clients wanting lower-intensity treatmentsIn-centre[AR26]
facematter professional skincare product lineCosmeceutical line developed by a team with more than 20 years of cosmeceutical experience; formulations for diverse skin concerns. Individual SKUs and pricing are not disclosed in filings.Existing clients and online consumersOwn e-shop (facematter.com) and a third-party shopping platform (platform not named)[AR26][WEB]

Anti-ageing & Preventive Medicine

OfferingDescriptionTarget customerSource
Personalised wellness plansComprehensive anti-ageing and preventive care plansHealth-conscious adults[WEB]
Genetic testingGenetic testing to inform preventive plansSame[WEB]
Anti-ageing medicine and supplementsAnti-ageing medicines and supplementsSame[WEB]
Health-management / body-check servicesComprehensive body-check service (website imagery); operated via the Rightway Honour sub-group ("Hong Kong Precision and Preventive Medical Centre" entities)Same[WEB][AR26]

Product refresh cadence. The group states it continuously performs market research on the latest products, skills, devices and technology. It regards new services and products as a key growth driver [WEB][AR26]. The FY2026 device refresh is evidenced by HK$1.75m of PP&E additions, of which HK$1.69m was medical equipment. This included a trade-in arrangement in which HK$619k of the purchase price was offset by disposal of existing equipment [AR26 notes 16, 37].

Financial Narrative

All figures are in HK$ thousands unless stated, from [AR26] including its five-year financial summary, except where noted. FY2022–FY2024 cost and cash-flow details come from aggregators [ETNET][MOO][STX] and are flagged.

Income statement

Notes:

  • FY2022–FY2024 staff costs come from [MOO]; directors' emoluments FY2022–FY2024 and D&A FY2022–FY2024 come from [ETNET]. Net finance cost comes from [ETNET] and reconciles to [AR26] for FY2025–FY2026 (finance costs less bank and lease-deposit interest income).

  • EBITDA = PBT + net finance cost + D&A. Under HKFRS 16 this excludes rent, because right-of-use depreciation is added back. It therefore overstates cash earnings; see EBITDA after leases in 6.4.

  • EPS for FY2023 and FY2022 is derived as attributable profit divided by 396,736k shares. FY2024 basic loss per share of HK0.77 cents is corroborated by press coverage [MOO].

  • A special dividend of HK2.5 cents was declared with the FY2021 results [STX][MOO].

Source conflict: FY2024 revenue is HK$49,135k per [AR26]/[ETNET] but HK$49,885k per [STX]/[TR]. The primary filing figure is used.

Revenue CAGR. FY2022–FY2026 (4-year): -0.7%. FY2016–FY2026 (10-year, aggregator series [STX], from about HK$60.1m): about -2.2%. Revenue has oscillated in a HK$41.7–49.9m band since FY2020 [STX][AR26].

FY2026 cost structure

Profit bridge, FY2025 to FY2026. Attributable result moved from HK$-3.38m to HK$+0.94m, a swing of about HK$4.3m:

Note that about HK$0.6m of FY2026 other income (PP&E disposal gain) is non-recurring. Excluding it, the underlying FY2026 pre-tax profit was about HK$0.3m.

Balance sheet

FY2024 cash and lease liabilities come from the opening balances in [AR26] cash flow statement and note 37. The FY2024 bank borrowing of nil comes from [AR26] note 37 (opening balance at 1 April 2024).

Commentary. Equity attributable to owners has eroded from HK$17.4m (FY2022) to HK$5.2m (FY2026). Three causes stand out:

  • cumulative losses of about HK$10.0m over FY2023–FY2025;

  • the October 2024 buy-out of the 49% minority in Rightway Honour, which transferred HK$3.374m of the subsidiary's net liabilities to owners' equity;

  • no capital raising.

The FY2025 jump in total assets to HK$57.4m reflects the HK$9.0m loan proceeds held as cash and the HK$15.0m right-of-use remeasurement on lease renewals. The balance sheet's defining feature is the HK$23.2m contract liability, a non-cash obligation to deliver future treatments. It creates the reported net current liability position (HK$-5.9m) even though unpledged cash and deposits of HK$16.7m exceed bank debt. The pledged deposits of HK$12.7m (HK$10.3m for merchant-acquiring services, HK$2.4m for the bank facility) are economically restricted [AR26 note 21].

Cash flow

Notes:

  • FY2022–FY2024 OCF comes from [STX], an aggregator. [STX] shows FY2026 OCF of HK$5,810k against HK$5,513k in [AR26], so the FY2022–FY2024 aggregator values should be treated as indicative.

  • FY2022 dividends paid are derived as HK$0.025 × 396.736m shares for the July 2021 special dividend [STX].

  • In [AR26], lease interest is presented within "interest paid" in financing activities. The lease-interest figure in this table comes from note 37.

  • FCF after leases = OCF − capex − lease principal − lease interest.

Commentary. Reported free cash flow looks healthy, but it is flattered by HKFRS 16. Once lease payments are deducted (HK$5.8m in FY2026, HK$7.6m in FY2025), the business generated negative cash in FY2026 (about HK$-1.5m). FY2025 benefited from a HK$4.4m inflow of customer prepayments. In FY2026 that reversed into a HK$2.1m outflow as package redemptions exceeded new sales.

Unpledged cash and deposits fell modestly from HK$17.3m to HK$16.7m. Group cash management also shifted: HK$5.2m was placed in six-month deposits, and HK$1.16m was used to buy a US$-denominated life insurance policy on an executive director, now pledged to the bank facility [AR26 notes 17, 21].

Ratios

Notes:

  • The ROE series reconciles to [WS], which shows a maximum annual ROE of 22.50% and a minimum of -80.50%.

  • The current ratio series comes from [VI] and reconciles to [AR26] for FY2025 and FY2026.

  • The FY2025 bank D/E of 2.15x reconciles to [SWS] (214.5%).

  • All other ratios are derived from [AR26].

Trend, inflection and driver commentary

  1. Revenue: range-bound, now volatile in alternate years. Revenue swung +17.8%, -7.3%, +7.9%, -8.2% and +6.1% over FY2022–FY2026. Management links the swings to the macro and consumption environment [AR26]: post-COVID reopening, outbound travel and northbound consumption by Hong Kong residents, weak non-residential property, and cautious consumers. Peers show the same pattern. Perfect Medical's revenue fell 14.7% in FY2026 [PMH26], and EC Healthcare's fell 8.9% [ECH26]. Medicskin's +6.1% therefore outperformed both larger peers in FY2026, albeit from a small base.

  2. Margin inflection in FY2026 was cost-led. The swing to profit was driven by lower rent (HK$1.9m) and lower staff costs (HK$1.1m) at least as much as by revenue (HK$2.8m) [AR26]. The rent saving is locked in until about February 2028 for the Central centre. The renewed Central rent from February 2028 is HK$295,200 per month (about HK$3.54m a year) [DT1006]. The current rent per centre is not separately disclosed, so the step-change cannot be computed.

  3. Founder cost burden. Dr. Kong's total remuneration was HK$6.08m in FY2026 (HK$6.78m in FY2025), equal to 12.7% of revenue. It exceeds the group's profit for the year by about 6.5 times. Part of this reflects his clinical role as a practising doctor in the group [AR26 note 9]. Even so, it is the single largest swing factor in reported profitability.

  4. Balance-sheet fragility. Group equity of HK$5.2m and net current liabilities of HK$5.9m leave little buffer. The going-concern basis rests on four supports: FY2026 operating cash inflow, a bank loan scheduled for monthly repayment to 2034 (despite an on-demand clause), no bank demand received, and HK$18.0m of undrawn facilities [AR26 note 3].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityPlace / date of incorporationOwnershipPrincipal activity

Multiple Profit Enterprise Limited

BVI, 1 Feb 2012

100% direct

Investment holding

Medicskin Laboratories Limited (美嫡絲肌科美有限公司)

HK, 12 Jul 2000

100% indirect

Medical skincare services (main operating company; tenant of Central centre)

—

HK, 19 Sep 2014

100% indirect

Skincare product sales and medical skincare services

互聯美(深圳)貿易有限公司

Shenzhen, PRC, 19 Aug 2015

100% indirect

Skincare product sales (WFOE)

香港精準及預防醫療中心有限公司 (incorporated 31 Mar 2017)

HK

100% indirect

Medical consultation services

Right Success Investment Development Limited

BVI, 18 Sep 2017

100% direct

Investment holding

Rightway Honour Holdings Limited

BVI, 18 Sep 2017

100% indirect (51% until 1 Oct 2024)

Investment holding (preventive-medicine sub-group)

香港精準及預防醫療中心有限公司 (incorporated 9 Oct 2017)

HK

100% indirect

Skincare and health-management services

Wealthy Plenty Limited

19 Sep 2017

100% direct

Investment holding

偉之健抗衰老健康管理(廣州)有限公司

Guangzhou, PRC, 1 Jun 2018

0% (100% at FY2025); disposed FY2026

Skincare product sales (dormant)

Revenue by Segment

Service line (HKD K)FY2024FY2025FY2026

Medical consultation services revenue

—1,035954

Prescription and dispensing services revenue

—8,5537,778

Treatment services revenue

—35,52039,139

Total revenue

49,13545,10847,871

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Service line share of revenue (%)

Service line share of revenue (%)FY2025FY2026

Medical consultation share (%)

2.32.0

Prescription and dispensing share (%)

19.016.2

Treatment services share (%)

78.781.8

Service line YoY growth (%)

Service line YoY growth (%)FY2024FY2025FY2026

Medical consultation YoY (%)

——-7.8

Prescription and dispensing YoY (%)

——-9.1

Treatment services YoY (%)

——10.2

Total revenue YoY (%)

7.9-8.26.1

Revenue by Segment and Segment Margins & Growth (%)

Metric (HKD K)FY2024FY2025FY2026

Segment revenue

49,13545,10847,871

Gross profit (revenue less inventories used)

—36,59038,792

Gross margin (%)

—81.181.0

Operating profit / EBIT (derived: PBT + net finance cost)

-3,273-3,7821,065

EBIT margin (%)

-6.7-8.42.2

Profit before tax

-3,124-3,463922

Pre-tax margin (%)

-6.4-7.71.9

Income Statement and Margin Analysis (%)

Metric (HKD K)FY2022FY2023FY2024FY2025FY2026

Revenue

49,14745,54149,13545,10847,871

Revenue growth (%)

17.8-7.37.9-8.26.1

Inventories used (cost of sales)

———8,5189,079

Gross profit

———36,59038,792

Staff costs (incl. directors)

20,54023,17024,62023,89022,801

Directors' emoluments

8,8208,8269,9519,5878,700

Depreciation & amortisation (RoU + PP&E)

9,7319,3259,3919,0647,165

Net finance cost (income)

-50282-149-319143

EBITDA (derived; HKFRS 16 basis)

14,1025,9046,1185,2828,230

Operating income / EBIT (derived)

4,371-3,421-3,273-3,7821,065

Profit before tax

4,421-3,703-3,124-3,463922

Income tax (expense) / credit

-276113228114

Profit for the year

4,145-3,590-3,102-3,382936

Profit attributable to owners

3,922-3,537-3,048-3,377936

EPS basic and diluted (HK cents)

0.99-0.89-0.77-0.850.24

Dividend per share declared (HK cents)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin (%)

Margin (%)FY2022FY2023FY2024FY2025FY2026

Gross margin (%)

———81.181.0

EBITDA margin (%)

28.713.012.511.717.2

Operating (EBIT) margin (%)

8.9-7.5-6.7-8.42.2

Pre-tax margin (%)

9.0-8.1-6.4-7.71.9

Net margin (%)

8.4-7.9-6.3-7.52.0

Staff cost to revenue (%)

41.850.950.153.047.6

Directors' emoluments to revenue (%)

17.919.420.321.318.2

Cost line (HKD K)

Cost line (HKD K)FY2025FY2026Change (%)Driver per [AR26]

Inventories used

8,5189,0796.6

In line with revenue (19.0% vs 18.9% of revenue)

Staff costs

23,89022,801-4.6

Lower directors' emoluments and staff salaries

RoU depreciation

7,1995,326-26.0

Lower rents on lease renewals for centres and office

PP&E depreciation

1,8651,839-1.4

Stable

Other expenses

8,1868,5124.0

In line with revenue; includes marketing

Finance costs

68990030.6

Lease interest up (HK$631k vs HK$394k) after renewals; bank loan interest HK$259k

Other income, gains and losses

1,7761,508-15.1

No repeat of HK$0.5m reinstatement provision write-back; bank interest down HK$0.2m; HK$0.2m fair value loss on insurance policy; partly offset by HK$0.6m PP&E disposal gain

Driver Details

DriverImpact (HKD Mn)

Revenue growth

+2.8

Less higher inventories used

-0.6

RoU depreciation savings

+1.9

Staff cost savings

+1.1

Higher other expenses

-0.3

Lower other income

-0.3

Higher finance costs

-0.2

Tax and NCI

Small

Balance Sheet

Metric (HKD K)FY2022FY2023FY2024FY2025FY2026

Total assets

56,66946,48440,06057,44351,067

Total liabilities

42,49035,88532,47953,24845,841

Total equity

14,17910,5997,5814,1955,226

Equity attributable to owners

17,43113,91210,9504,1955,226

Cash and bank balances incl. 6-month deposits (unpledged)

——6,92717,34416,734

Pledged bank deposits

———13,93212,724

Bank borrowings (all classified current)

——09,0008,927

Lease liabilities, current

———5,1475,092

Lease liabilities, non-current

———8,6473,555

Total lease liabilities

——5,75713,7948,647

Total debt incl. leases

——5,75722,79417,574

Net debt incl. leases (excl. pledged deposits)

——-1,1705,450840

Net debt excl. leases

——-6,927-8,344-7,807

Goodwill and intangibles

———00

Contract liabilities (prepaid packages)

——20,99825,35923,222

Net current assets (liabilities)

———-6,168-5,907

Inventories

———3,6323,619

Right-of-use assets

———14,0318,705

Cash Flow

Metric (HKD K)FY2022FY2023FY2024FY2025FY2026

Operating cash flow

4,2943,24610,5169,1325,513

Capex (PP&E purchases)

———8451,268

Free cash flow (OCF less capex)

———8,2874,245

Lease principal repaid

———7,2455,147

Lease interest paid

———394631

FCF after lease payments

———648-1,533

Dividends paid

9,9180000

Share buybacks

———00

Change in contract liabilities (working capital)

———4,361-2,137

EBITDA after lease payments (EBITDAaL, derived)

———-2,3572,452

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE on closing attributable equity (%)

22.5-25.4-27.8-80.517.9

ROA on closing total assets (%)

7.3-7.7-7.7-5.91.8

ROIC, EBIT / (equity + total debt − cash) (%)

——-51.1-39.217.6

Current ratio (x)

1.010.910.930.860.86

Debt / equity incl. leases (x)

——0.765.433.36

Bank debt / equity (x)

——0.002.151.71

Gearing per company definition: interest-bearing debt / total assets (%)

——14.439.734.4

Net debt incl. leases / EBITDA (x)

——-0.191.030.10

EBITDA / finance costs (x)

———7.79.1

EBIT / finance costs (x)

———-5.51.2

Asset turnover (x)

0.870.981.230.790.94

Inventory days

———156146

Receivable days

———53

Payable days

———3331

Cash conversion cycle, accounting basis (days)

———128118

Region revenue (HKD K)

Region revenue (HKD K)FY2022FY2023FY2024FY2025FY2026

Hong Kong revenue

49,14745,54149,13545,10847,871

Mainland China revenue

00000

Rest of world revenue

00000

Region growth (%)

Region growth (%)FY2022FY2023FY2024FY2025FY2026

Hong Kong revenue growth (%)

17.8-7.37.9-8.26.1

Service Line Details

Service line (HKD K)Hong KongMainland ChinaTotal

Medical consultation

9540954

Prescription & dispensing

7,77807,778

Treatment services

39,139039,139

Total

47,871047,871

Share Price History

DatePrice (HKD)Implied market cap (HKD Mn)

18 Dec 2014 (IPO)

0.600238.0

about 1 Oct 2025

about 0.138 (implied)

54.75

about 8 Nov 2025

about 0.199 (implied)

78.95

3 Apr 2026

0.16967.05

24 Apr 2026

0.14356.7

10 Jul 2026

0.11846.8

22 Jul 2026 (latest verified)

0.12348.8

Share Price & Returns

HorizonPerformance

1-year

About -28% (market cap -27.6% year-on-year at 10 Jul 2026); Simply Wall St shows -29% at HK$0.14

1-quarter (to 10 Jul 2026)

-21.0%

Since Jan 2017

-87.2%

Since IPO

-79.5% on unadjusted HK$0.60 vs HK$0.123. Stoxray shows -96.5%; the discrepancy (possibly dividend or other adjustment) could not be reconciled.

52-week range

HK$0.025–0.240 per [SA]. The low appears anomalous and may be a data error.

Beta

-0.14 (illiquid; not meaningful)

Valuation Multiples

MultipleMedicskin (8307)EC Healthcare (2138)

Market cap (HKD Mn)

48.8

about 474 at HK$0.40

P/E (x)

52.1

n/m (loss)

P/B (x)

9.3

Not computed

EV / Sales (x), incl. leases

1.04

Not computed

EV / EBITDA (x), HKFRS 16 incl. leases

6.0

n/m (LBITDA HK$-110.1m)

EV / EBITDAaL (x), ex-leases

16.7—

P/S (x)

1.02

about 0.13

Dividend (HK cents per share)

Dividend (HK cents per share)FY2022FY2023FY2024FY2025FY2026

Interim and final dividend per share (HK cents)

00000

Debt Maturity Profile

Maturity bucketBank borrowings (scheduled)Lease liabilities

Within 1 year

8515,092

1–2 years

1,0473,555

2–5 years

3,3200

Over 5 years

3,7090

Total

8927

8647

Analyst Conclusions

Management guidance

No quantitative guidance is provided. Management's qualitative outlook for 2026 [AR26]:

  • persistent geopolitical and macro uncertainty;

  • intense competition;

  • encouraging signs of recovery in Hong Kong retail and services;

  • steady medium- to long-term demand growth in medical aesthetics.

Planned actions are continued operational optimisation, refined marketing, and renovation of the medical skincare centre(s).

Consensus growth expectations

There is no consensus because there is no coverage. The analyst base case, derived for FY2027:

Revenue: flat to low single-digit growth. Treatment demand is supportive, but the 16.5% fall in new prepaid package receipts and the 8.4% decline in contract liabilities point to softer recognisable revenue ahead.

Profitability: near break-even. The FY2026 profit included a non-recurring HK$0.6m disposal gain, and renovation-related disruption or costs may weigh.

Bull case

  1. Operating leverage on a fixed cost base. Rent savings are locked in until about 2028, and staff costs are already reduced. Each incremental HK$1m of revenue at about 81% gross margin drops largely to profit. A return to the FY2022 revenue level (HK$49.1m) would roughly double FY2026's underlying profit.

  2. Regulatory moat strengthening. Hong Kong's push to reserve injectables and high-risk procedures for doctors [CIS][LEGCO] structurally favours Medicskin's physician-led model over non-medical salons.

  3. Peer retrenchment opens share. Perfect Medical is closing underperforming Hong Kong outlets, and EC Healthcare is loss-making [PMH26][ECH26]. Medicskin grew 6.1% while both shrank. A renovated Central flagship with tenure to 2030 could capture displaced high-end clients.

Bear case

  1. Backlog drawdown masks weakening bookings. FY2026 treatment revenue was helped by recognising HK$19.2m of opening contract liabilities, while new package receipts fell to HK$17.1m. Sustained weakness would hit both revenue and cash. FCF after leases was already negative (about HK$-1.5m).

  2. Key-person and governance risk. The 72-year-old founder is Chairman, CEO, controlling shareholder (69.3%) and practising doctor. He takes HK$6.1m in remuneration, about 6.5 times group profit, and personally guarantees the bank facilities. No succession plan is disclosed.

  3. Fragile capital base and valuation. Equity is HK$5.2m, net current liabilities are HK$5.9m, and debt including leases is 3.4x equity. The stock trades at 52x earnings and 9.3x book with negligible liquidity and no dividend capacity. Any return to losses would quickly erode equity and could pressure bank covenants or GEM listing standing.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhat to watch
Interim results, six months to 30 Sep 2026By about mid-Nov 2026 (board meeting notice filed 29 Sep 2026)Treatment revenue growth; contract-liability trend (new package sales); staff-cost discipline
Centre renovationTiming undisclosedCapex size, disruption to Central centre revenue, financing
Lease renewal for TST / Ocean CentreBefore current leases expire (all lease liabilities run off within 2 years)Rent level vs current; RoU remeasurement
Hong Kong regulatory developmentsOngoingMedical-device / high-risk procedure legislation; injectable classification implementation
Founder succession or board refreshAny timeINED tenure over 9 years for two directors; any CEO succession signals
Capital actionsAny timeUse of buy-back mandate; any placing (equity is thin); dividend resumption unlikely
FY2027 annual resultsAbout June 2027Sustainability of profit without the one-off disposal gain

Concluding analyst verdict

Medicskin Holdings is a well-run but structurally constrained boutique: two doctor-led medical aesthetics clinics inside a GEM-listed shell. Its FY2026 turnaround is genuine but modest. Revenue rose 6.1% to HK$47.9 million against double-digit declines at larger peers, and the group swung from a HK$3.4 million loss to a HK$0.9 million profit. The quality of that profit, however, deserves scrutiny.

Roughly two-thirds of the improvement came from cost actions, mainly lower rents on lease renewals and reduced staff and director pay, rather than from demand. About HK$0.6 million of the result was a non-recurring equipment disposal gain. The underlying operating profit is therefore close to break-even.

The prepaid-package model is both the group's financial strength and its blind spot. Customer prepayments of HK$23.2 million fund operations and give revenue visibility. But FY2026 receipts from new packages fell 16.5%, and contract liabilities shrank. That suggests FY2026 treatment growth partly consumed the backlog rather than rebuilding it. After lease payments, the business consumed cash.

Governance and capital structure are the binding constraints:

  • The founder controls 69% of the equity and combines the Chair, CEO and lead-clinician roles.

  • He receives remuneration several times group profit and personally guarantees the bank facilities.

  • Equity is only HK$5.2 million, and net current liabilities persist.

The early extension of the Central flagship lease to 2030 and the planned renovation signal commitment to the core franchise. They also add fixed-cost and capex risk.

At HK$0.123, the market values the company at about HK$49 million: 52x trailing earnings, 9.3x book and about 17x rent-adjusted EBITDA. For a sub-scale, illiquid, controlled micro-cap with no dividend capacity and no stated succession plan, this valuation already discounts a sustained recovery.

The analytical stance is cautious. The business is viable and clinically credible, but evidence of rebuilding prepaid bookings is needed before the FY2026 inflection can be treated as durable. The interim results due around November 2026 are the next decisive data point.


Appendix A: Data limitations and conflicts

  1. FY2024 revenue: HK$49,135k per [AR26]/[ETNET] vs HK$49,885k per [STX]/[TR]. The primary filing figure is used.

  2. FY2026 operating cash flow: HK$5,513k per [AR26] vs HK$5,810k per [STX]. The primary figure is used; FY2022–FY2024 OCF comes only from [STX] and is indicative.

  3. Distributable reserves: the AR26 directors' report says none at company level, while the financial statements show positive reserves at company (HK$1,081k) and group (HK$1,259k) level.

  4. Workforce gender ratio: the AR26 CG report text (21:79 female:male) conflicts with the ESG chart and narrative (about 79% female).

  5. Since-IPO share performance: -79.5% unadjusted vs -96.5% per [STX]; not reconciled.

  6. 52-week low: HK$0.025 per [SA] appears anomalous.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleAppointed / tenureAgeEducation / credentialsPrior roles / other

Dr. Kong Kwok Leung (江覺亮)

Chairman, CEO, Executive Director; founder and practising doctor; Chair of Nomination Committee; member of Remuneration Committee

Founder (2000); listed-co director since 2014

72

MBBS (HKU, 1978); DCH (RCP London, 1985); Dip Dermatology (Univ. of London, 1995); PG Dip Practical Dermatology (Cardiff, 2007)

Over 40 years in private practice; over 30 years in medical aesthetics. Domestic partner of Ms. Tsui Kan; uncle of Ms. Kong Chung Wai.

Ms. Tsui Kan (徐勤)

Executive Director; Vice President

Joined Jan 2016

42

LLB, Zhejiang University (2004)

Oversees product development and marketing strategy; domestic partner of Dr. Kong

Ms. Kong Chung Wai (江聰慧)

Executive Director; Legal & Compliance Officer; Compliance Officer; authorised representative; Nomination Committee member

Joined 2001

48

BBA Accounting (HKUST, 2000); LLB (Univ. of London, 2010); FCCA since 2010

Over 25 years in accounting, audit and compliance; niece of Dr. Kong

Ms. Sin Chui Pik Christine (冼翠碧)

Executive Director; CFO; Company Secretary; Remuneration Committee member

Joined Mar 2014; Company Secretary since 23 Jun 2014

47

BBA Accounting (HKBU, 2001); FCPA; FCCA

Deloitte Touche Tohmatsu 2001–2004 and 2005–2014 (Manager). INED of Zhongxing Group Holdings (55.HK) since Sep 2023.

Mr. Chan Cheong Tat (陳昌達)

INED; Chair of Audit Committee

3 Dec 2014 (over 11 years)

76

MFin Mgmt (Central Queensland Univ., 1995); FCPA, FCCA, CPA Australia; Chartered Secretary

Hong Kong Inland Revenue Department for over 32 years (retired 2005 as Assistant Commissioner). Sole director of a tax advisory firm since 2006. INED of 8512, 8537, 1941 and 3393; formerly INED of 1283 (Sep 2019–Mar 2026).

Mr. Leung Siu Cheung (梁兆祥)

INED; Chair of Remuneration Committee

3 Dec 2014 (over 11 years)

74

Law Society Finals (1982); LLM Chinese & Comparative Law (CityU, 2004)

Practising solicitor since Oct 1983; partner of a Hong Kong law firm since 1986; also qualified in England & Wales and in ACT and NSW, Australia

Mr. Lui Sze On (呂思安)

INED

6 Sep 2023

53

Not specified

Over 20 years of service-industry management; major hotel groups 1989–2018; office administration centre manager, China Resources (Holdings) 2021–2023

—

Head of Business & Product Development; Medicskin Centre Manager (senior management, non-board)

Joined Jan 2013

46

BSc Nutritional Sciences (UBC, 2002); Advanced Diploma in International Administrative Management (2006)

Product manager at a cosmetics company 2007–2012; business development roles 2004–2007

Directors' Remuneration

Director (HKD K)FeesSalary & allowancesPerformance bonusService feesPensionTotal FY2026Total FY2025

Dr. Kong Kwok Leung

604,3201,698006,0786,776

Ms. Tsui Kan

6048520018583764

Ms. Kong Chung Wai

60004110471455

Ms. Sin Chui Pik Christine

60916340181,0281,052

Mr. Chan Cheong Tat

1800000180180

Mr. Leung Siu Cheung

1800000180180

Mr. Lui Sze On

1800000180180

Total

7805,7211,75241136

8700

9587

Governance Overview

AttributeStatus

Board size

7 (4 executive, 3 INEDs)

Independence

43% independent (minimum 3 INEDs per GEM Rule 5.05)

Gender diversity

3 of 7 directors female (43%); no numerical target set

Chair / CEO separation

Not separated. Dr. Kong holds both roles, a disclosed deviation from CG Code C.2.1

Family relationships on board

Chairman's domestic partner (Tsui) and niece (Kong CW) are executive directors

INED tenure

Two of three INEDs have served over 9 years; separate shareholder resolutions approved at the 2024 AGM

Committees

Audit (3 INEDs; chair Chan); Remuneration (chair Leung; 2 EDs + 3 INEDs); Nomination (chair Dr. Kong; 2 EDs + 3 INEDs). Committee terms of reference re-published 22 Jun 2026.

Meetings FY2026

Board 4 (100% attendance); Audit 4; Remuneration 1; Nomination 1; Chairman–INED meetings 2

AGM attendance

Ms. Tsui and Ms. Kong CW did not attend the 15 Sep 2025 AGM

Corporate governance committee

None; the board performs CG functions

Whistleblowing

Policy in place; reports escalate to the Audit Committee chair

D&O insurance

In place

Major Shareholders

HolderShares% of issuedType

Topline Worldwide Limited (wholly owned by Dr. Kong Kwok Leung)

274,865,40069.28

Controlling shareholder (insider)

Public float (no other holder above 5% disclosed)

121,870,60030.72

Public

Competitive Landscape

Key Competitors

CompetitorTypeLatest revenueRelative positioning vs Medicskin

Perfect Medical Health Management (1830.HK)

Listed multi-brand medical aesthetics chain (HK, PRC, Macau, Australia, Singapore)

FY2026 HK$962.3m; profit HK$178.3m; payout of 100% or more for 11 straight years; rightsizing HK outlets; Oracle (Korea) cooperation

About 20x Medicskin's revenue; scale purchasing, marketing reach, zero-borrowing balance sheet

EC Healthcare (2138.HK)

Listed non-hospital healthcare platform (medical, aesthetic medical, beauty and wellness, veterinary)

FY2026 HK$3,770.2m total; aesthetic medical and beauty & wellness HK$1,322.9m; net loss HK$412.9m

Aesthetic segment about 28x Medicskin's revenue; one-stop ecosystem; financially strained

Modern Beauty Salon Holdings (919.HK)

Listed beauty-salon and wellness chain

—

Lower-acuity beauty services; price competitor for non-medical treatments

Natural Beauty Bio-Technology (157.HK)

Listed beauty-services and skincare group

—

Skincare and beauty-services overlap with facematter

Medilase (private)

Hong Kong laser-aesthetics clinic chain

—

Direct competitor in laser and energy-based treatments

Independent dermatologist and doctor-run aesthetic clinics (Central, TST)

Fragmented private practices

—

Same doctor-led proposition; compete for doctors and clients

Non-medical beauty salons

Fragmented

—

Cheaper, less regulated alternatives

Shenzhen medical-aesthetic clinics (northbound consumption)

Cross-border substitute

—

Lower prices; drain on Hong Kong local demand

Korean and Japanese aesthetic clinics (outbound medical tourism)

Cross-border substitute

—

Outbound travel diverts spending

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricMedicskin (8307)Perfect Medical (1830)EC Healthcare (2138)

Revenue (HKD Mn)

47.9962.33,770.2

Revenue growth (%)

6.1-14.7-8.9

Profit for the year (HKD Mn)

0.9178.3-412.9

Net margin (%)

2.018.5-11.0

Aesthetic / beauty revenue (HKD Mn)

47.9

Not separated in data reviewed

1,322.9

Contract liabilities / deferred revenue (HKD Mn)

23.2

196.4 (2.7 + 193.7)

539.1

Dividend

—

HK14.6 cents (payout 102.8%)

—

Recent Developments

Company-specific events are drawn from the announcements register on [WEB] and the content of [AR26], [PPA26] and [DT1006]. Industry and peer events are included where they directly affect Medicskin's operating context.

The register shows no first-quarterly results for the quarter to 30 June 2026. The annual report refers to quarterly reports only "if any", consistent with GEM no longer requiring mandatory quarterly reporting [WEB][AR26].

Company Snapshot

$6.1M

Revenue

42

Employees

2000

Founded

Grand Cayman, Cayman Islands

Headquarters

SWOT Analysis

Strengths

  • High unit gross margin: Gross margin 81.0% in FY2026 (inventories used HK$9.1m on revenue HK$47.9m) [AR26]
  • Customer-funded working capital: Contract liabilities HK$23.2m (about 48% of revenue), recognised over 12–36 months [AR26]
  • Loyal, diversified client base: Most clients have patronised the group for more than 5 years; top 5 customers under 4.4% of revenue [AR26]
  • Physician-led clinical credibility: Founder holds HKU MBBS and three dermatology and paediatric diplomas, with over 30 years in medical aesthetics; most treatments are doctor-performed [AR26]
  • Prime, secured flagship site: Central flagship leased since 2016 and renewed to Feb 2030 [DT1006]
  • Revenue resilience vs peers in FY2026: +6.1% growth against Perfect Medical -14.7% and EC Healthcare -8.9% [AR26][PMH26][ECH26]
  • Undrawn liquidity backstop: HK$18.0m of undrawn bank facilities; unpledged cash and deposits HK$16.7m [AR26]

Weaknesses

  • Sub-scale footprint: Only two centres; revenue HK$47.9m, about 5% of Perfect Medical's [AR26][PMH26]
  • Heavy fixed-cost base: Staff costs 47.6% and directors' emoluments 18.2% of revenue in FY2026 [AR26]
  • Thin equity and negative working capital: Equity HK$5.2m; net current liabilities HK$5.9m; debt/equity including leases 3.4x [AR26]
  • Key-person and governance concentration: 72-year-old founder is Chairman, CEO and doctor; Chair and CEO roles not separated; domestic partner and niece on board [AR26]
  • Declining medical and product lines: Consultation -7.8% and prescription & dispensing -9.1% in FY2026 [AR26]
  • Weak cash generation after rent: FCF after lease payments HK$-1.5m in FY2026 [AR26 derived]
  • Weakening forward bookings: New prepaid package receipts down 16.5% to HK$17.1m; contract liabilities down 8.4% [AR26 note 23]

Opportunities

  • Regulatory tightening favours doctor-led clinics: April 2026 injectable classification clarification; ongoing high-risk procedure and device regulation [CIS][LEGCO]
  • Mainstreaming of non-invasive aesthetics: Management cites growing acceptance and steady medium- to long-term demand [AR26]
  • Centre renovation to lift spend per client: Planned renovation; lease extended to 2030 to support it [AR26][DT1006]
  • Technology refresh: Ultherapy PRIME® launched in FY2026; device-led marketing campaigns [AR26]
  • Preventive and anti-ageing medicine: Unit now 100% owned (Oct 2024); offers genetic testing and wellness plans [AR26][WEB]
  • Peer rightsizing reduces competitive intensity: Perfect Medical closing underperforming Hong Kong outlets; EC Healthcare loss-making [PMH26][ECH26]
  • Omnichannel skincare: facematter e-shop plus a third-party platform [AR26]

Threats

  • Cross-border substitution: Outbound travel and northbound consumption diverting local demand [AR26][ECH26]
  • Doctor scarcity: Limited supply of qualified registered doctors; competition to recruit them [AR26]
  • Rent reset risk: Central rent from Feb 2028 is HK$295,200/month; all current lease liabilities mature within 2 years [DT1006][AR26]
  • Reputational and media sensitivity: Industry sensitive to adverse media; 5 negative feedback cases in FY2026 against 3 in FY2025 [AR26]
  • Regulatory compliance cost: Government review of standards for medical aesthetic procedures [AR26]
  • Labour-law cost inflation: MPF offset abolition from 1 May 2025 raises LSP liabilities [AR26]
  • Funding and bank dependence: HK$8.9m loan with an on-demand clause; facilities personally guaranteed by Dr. Kong [AR26]

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Feb 2025 (context)Lease renewals signed (Central lease to Feb 2028) [AR26][DT1006]Basis for FY2026 rent savings
1 May 2025Hong Kong MPF offsetting abolition takes effect [AR26]Raises future long-service-payment liability (LSP obligation HK$972k at FY2026)
May 2025Bank extends repayment schedule of HK$9.0m SFGS loan [AR26]Liquidity relief; monthly amortisation now to 2034
Jun 2025Third consecutive annual loss
15 Sep 20252025 AGM held (two EDs absent) [AR26]Routine; governance attendance gap
30 Sep 2025Dr. Kong's interest confirmed at 69.28% [ETNET]Control unchanged
Nov 2025—
FY2026 (date n/d)Launch of Ultherapy PRIME® [AR26]Treatment menu upgrade
FY2026 (date n/d)Purchase of US$ life insurance policy on an executive director (HK$1.16m) [AR26]Treasury/collateral use; HK$0.2m FV loss
FY2026 (date n/d)Disposal of Guangzhou subsidiary to Dr. Kong's elder brother [AR26]PRC footprint shrinks
FY2026 (date n/d)Medical equipment trade-in; HK$614k disposal gain [AR26]One-off boost to FY2026 profit
FY2026 (date n/d)HK$244k business-development fee to entity owned by ED Tsui's mother [AR26]Related-party transaction (exempt)
Mar 2026INED Chan Cheong Tat steps down from his INED role at 1283.HK [AR26]Reduces his outside directorship load
Apr 2026Hong Kong clarifies that injectable products are regulated as pharmaceutical products by default [CIS]Supports doctor-only injectables; possible product-access constraints
1 Jun 2026Monthly return (May 2026) [WEB]Routine
2 Jun 2026Notice of board meeting to approve FY2026 results [WEB]Routine
12 Jun 2026Positive profit alert: expects FY2026 attributable profit of HK$0.5–1.5m against a HK$3.4m loss, citing higher treatment clients and visits plus rent savings [PPA26]Turnaround signalled
22 Jun 2026FY2026 annual results: revenue HK$47.9m (+6.1%); attributable profit HK$0.9m; EPS HK0.24 cents; no dividend [AR26]First profit since FY2022
22 Jun 2026Revised terms of reference for Audit, Remuneration and Nomination Committees published [WEB]Governance housekeeping (CG Code alignment)
26 Jun 2026Annual Report 2025/26 (including ESG report), AGM circular (general mandates to issue and buy back shares; re-elections; auditor re-appointment), AGM notice and proxy form [WEB]Routine; buy-back mandate sought
29 Jun 2026Peer EC Healthcare reports FY2026 revenue -8.9% and net loss widening to HK$412.9m [ECH26]Sector-wide demand weakness
30 Jun 2026Peer Perfect Medical reports FY2026 revenue -14.7% to HK$962.3m; profit HK$178.3m; H2 decline narrows to -6.1% [PMH26]Sector bottoming signals
2 Jul 2026Monthly return (June 2026) [WEB]Routine
10 / 22 Jul 2026Shares quoted at HK$0.118 / HK$0.123; market cap about HK$47–49m [SA][ETNET]Valuation reference
3 Aug 2026Monthly return (July 2026) [WEB]Routine
6 Aug 2026AGM poll results announced [WEB]Re-elections and mandates
1 Sep 2026Monthly return (August 2026) [WEB]Routine
29 Sep 2026Notice of board meeting (likely for interim results to 30 Sep 2026; due under GEM rules within 45 days of period end) [WEB]Next earnings catalyst
5 Oct 2026Monthly return (September 2026) [WEB]Routine
6 Oct 2026Discloseable transaction: early renewal of Central flagship lease for Feb 2028–Feb 2030 at HK$295,200/month, about HK$5.4m RoU asset; renovation planned [DT1006]Secures flagship site; signals renovation capex

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue fell from HKD 49.1 Mn in FY2022 to HKD 47.9 Mn in FY2026.
Medicskin Holdings Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue49.145.549.145.147.9
Inventories used (cost of sales)———8.59.1
Gross profit———36.638.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.